Every Form 4 that Genenta Science Spa (GNTA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow GNTA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GNTA filings page.
Genenta Science S.p.A. reported that Chief Executive Officer Pierluigi Paracchi received a grant of stock options for 100,000 American Depositary Shares. The options have an exercise price of $0.63 per share and expire on December 31, 2035.
According to the grant terms, the options vest in equal monthly installments over three years beginning March 30, 2026, meaning the award becomes exercisable gradually rather than all at once. After this grant, Paracchi holds stock options covering 100,000 ADSs directly under this award.
Genenta Science S.p.A. reported that its CMO & Head of Development, Francesco Galimi, received a grant of stock options covering 20,000 American Depositary Shares. The options have an exercise price of $0.63 per share and expire on December 31, 2035.
The options vest in equal monthly installments over one year beginning March 30, 2026. Following this grant, Galimi holds stock options for 20,000 ADS directly, reflecting a compensation-related award rather than an open-market transaction.
Genenta Science S.p.A. director Giacomoantonio Paracchi reported a compensation-related grant of stock options. On March 30, 2026, he was awarded options covering 20,000 American Depositary Shares at an exercise price of $0.63 per share, expiring on December 31, 2035.
The options vest in equal monthly installments over one year beginning March 30, 2026, aligning the award with ongoing service. Following this grant, Paracchi holds 20,000 stock options directly.
Genenta Science S.p.A. director Sharei Armon received a grant of stock options for 20,000 American Depositary Shares. The options have an exercise price of $0.63 per share and expire on December 31, 2035. They vest in equal monthly installments over one year beginning March 30, 2026.
Genenta Science S.p.A. director Mutti Miguel Maria received a grant of stock options covering 20,000 American Depositary Shares. The options were granted at no cost, with an exercise price of $0.63 per share and an expiration date of December 31, 2035.
The options vest in equal monthly installments over one year beginning March 30, 2026, aligning the director’s compensation with longer-term company performance. Following this grant, the director holds 20,000 stock options directly, with no open-market share purchases or sales reported in this filing.
Genenta Science S.p.A. reported that Chief Financial Officer Richard B. Slansky received a grant of stock options covering 80,000 American Depositary Shares. The options have an exercise price of $0.63 per share and expire on December 31, 2035.
The award was granted at no cost and is a compensation-related acquisition, not an open-market purchase. According to the footnote, the options vest in equal monthly installments over three years beginning March 30, 2026, and all 80,000 options were reported as held directly following the transaction.